Gene therapy approaches to ventricular tachyarrhythmias
- PMID: 17993320
- PMCID: PMC2121616
- DOI: 10.1016/j.jelectrocard.2007.05.036
Gene therapy approaches to ventricular tachyarrhythmias
Abstract
Ventricular tachycardia arising from a healed myocardial infarction scar continues to be a significant cause of morbidity and mortality. Drug therapy has been inadequate to meet this challenge, and implantable devices are limited by expense and technical problems. We have proposed the use of gene therapy for cardiac arrhythmias. In this review, we present a model of postinfarct ventricular tachycardia, a method for gene delivery to this area, and results of KCNH2-G628S gene transfer to manipulate cellular refractory properties in the arrhythmia model.
Figures
References
-
- American Heart Association . 2001 Heart and Stroke Statistical Update. American Heart Association; Dallas, TX: 2002.
-
- Maisel W, Moynahan M, Zuckerman B, Gross T, Tovar O, Tillman D, Schultz D. Pacemaker and ICD generator malfunctions. JAMA. 2006;295:1901–1906. - PubMed
-
- Gould P, Krahn A. Canadian Heart Rhythm Society Working Group on Device Advisories. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA. 2006;295:1907–1911. - PubMed
-
- Estes N. Primary prevention of sudden cardiac death: a rational approach to the use of the implantable cardioverter defibrillator. J Int Card EP. 2005;13:91–93. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
